test44
https://www.cytel.com/blog/cytel-australian-research-council-collaborate-to-strengthen-early-phase-capabilities
May 16, 2022
A combination of industry and policy forces have recently changed the shape of Australia’s R&D sector, making it a..
Read article
test44
https://www.cytel.com/blog/leveraging-external-data-for-efficient-trial-designs
June 25, 2021
The main challenge associated with the development of therapies for rare diseases is typically the small study sample..
Read article
test44
https://www.cytel.com/blog/bayesian-methods-paving-the-path-to-clinical-development-transformation
June 4, 2021
Bayesian methods have been playing a key role in transforming clinical research in therapeutic areas such as oncology..
Read article
test44
https://www.cytel.com/blog/career-perspectives-tina-checchio
January 30, 2019
QPP remains at the heart of model based drug development. Short for Quantitative Pharmacology & Pharmacometrics, it..
Read article
test44
https://www.cytel.com/blog/non-compartmental-analysis
June 28, 2018
By Esha Senchaudhuri With thanks also to Jitendarreddy Seelam and Ramanatha Saralaya for their input. The fact of the..
Read article
test44
https://www.cytel.com/blog/inside-the-oncology-statistician-toolkit
February 9, 2017
In this blog, Adam Hamm, PhD, Director Biostatistics at Cytel shares some of the most important knowledge he uses..
Read article
test44
https://www.cytel.com/blog/case-study-blrm-oncology
test44
https://www.cytel.com/blog/subgroup-analysis-eugm-16
May 10, 2016
We were fortunate to welcome Björn Bornkamp of Novartis to the EUGM 2016 presenting work he has developed..
Read article
test44
https://www.cytel.com/blog/dual-agent-dose-escalation
April 22, 2016
FDA draft guidance on “Co development of two or more unmarketed investigational drugs for use in combination” notes..
Read article
